Stock Yards Bank & Trust Co. Sells 408 Shares of Medtronic PLC (MDT)

Stock Yards Bank & Trust Co. cut its stake in Medtronic PLC (NYSE:MDT) by 12.1% in the fourth quarter, Holdings Channel reports. The fund owned 2,959 shares of the medical technology company’s stock after selling 408 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Medtronic were worth $270,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Highwater Wealth Management LLC acquired a new stake in shares of Medtronic during the 4th quarter worth about $39,000. IMS Capital Management acquired a new stake in shares of Medtronic during the 3rd quarter worth about $41,000. Contravisory Investment Management Inc. increased its position in shares of Medtronic by 220.0% during the 4th quarter. Contravisory Investment Management Inc. now owns 480 shares of the medical technology company’s stock worth $44,000 after purchasing an additional 330 shares during the last quarter. Cornerstone Advisors Inc. increased its position in shares of Medtronic by 12.2% during the 3rd quarter. Cornerstone Advisors Inc. now owns 1,165 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 127 shares during the last quarter. Finally, Polaris Greystone Financial Group LLC increased its position in shares of Medtronic by 255.1% during the 3rd quarter. Polaris Greystone Financial Group LLC now owns 1,321 shares of the medical technology company’s stock worth $130,000 after purchasing an additional 949 shares during the last quarter. 80.76% of the stock is owned by institutional investors and hedge funds.

Shares of Medtronic stock opened at $86.03 on Wednesday. Medtronic PLC has a 12 month low of $76.41 and a 12 month high of $100.15. The stock has a market cap of $113.82 billion, a P/E ratio of 18.04, a PEG ratio of 2.21 and a beta of 0.93. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.56 and a quick ratio of 2.11.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 20th. The medical technology company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.15 by $0.07. Medtronic had a return on equity of 13.51% and a net margin of 7.44%. The company had revenue of $7.48 billion during the quarter, compared to analysts’ expectations of $7.35 billion. During the same period last year, the business posted $1.07 EPS. Medtronic’s revenue for the quarter was up 6.1% on a year-over-year basis. As a group, equities analysts expect that Medtronic PLC will post 5.13 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 18th. Stockholders of record on Friday, December 28th will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 2.32%. The ex-dividend date of this dividend is Thursday, December 27th. Medtronic’s payout ratio is presently 41.93%.

MDT has been the subject of a number of recent analyst reports. Citigroup downgraded Medtronic from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $109.00 to $96.00 in a research report on Wednesday, January 2nd. ValuEngine downgraded Medtronic from a “buy” rating to a “hold” rating in a research report on Monday, January 7th. JPMorgan Chase & Co. raised Medtronic from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $100.00 to $109.00 in a research report on Wednesday, December 19th. Argus raised their price objective on Medtronic from $108.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, October 8th. Finally, Barclays initiated coverage on Medtronic in a research report on Monday, October 15th. They set an “overweight” rating and a $113.00 price objective for the company. Nine equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $104.18.

In related news, CFO Karen L. Parkhill acquired 3,000 shares of the firm’s stock in a transaction dated Wednesday, January 9th. The stock was acquired at an average price of $83.87 per share, for a total transaction of $251,610.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Omar Ishrak acquired 12,000 shares of the firm’s stock in a transaction dated Wednesday, January 9th. The stock was bought at an average price of $84.05 per share, with a total value of $1,008,600.00. The disclosure for this purchase can be found here. Company insiders own 0.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.themarketsdaily.com/2019/01/16/stock-yards-bank-trust-co-sells-408-shares-of-medtronic-plc-mdt.html.

Medtronic Company Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Further Reading: Is a Roth IRA right for you?

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply